Support Care Cancer (2018) 26:1273–1279 https://doi.org/10.1007/s00520-017-3950-y ORIGINAL ARTICLE Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer 1 2 3 4 Joseph S. Bubalo & Jon D. Herrington & Marc Takemoto & Patricia Willman & 5 6 7 1 7 Michael S. Edwards & Casey Williams & Alan Fisher & Alison Palumbo & Eric Chen & 1 1 Charles Blanke & Charles D. Lopez Received: 10 May 2017 /Accepted: 25 October 2017 /Published online: 31 October 2017 Springer-Verlag GmbH Germany 2017 Abstract orally on day 1 and 80 mg on days 2 and 3. Palonosetron Purpose Chemotherapy-induced nausea and vomiting 0.25 mg was given IV push on day 1 only. Dexamethasone (CINV) causes significant morbidity among colorectal cancer 12 mg was administered orally on day 1 and 8 mg each morn- patients, receiving fluorouracil, oxaliplatin, and leucovorin ing on days 2 through 4. Assessments including emetic events, (FOLFOX) chemotherapy even with standard antiemetic pro- rescue doses, nutritional intake, and appetite were recorded in phylaxis. The purpose of this study is to determine if the a patient
Supportive Care in Cancer – Springer Journals
Published: Oct 31, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
It’s easy to organize your research with our built-in tools.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud